246 related articles for article (PubMed ID: 28886134)
21. Utility of High-Sensitivity Modified Glasgow Prognostic Score in Cancer Prognosis: A Systemic Review and Meta-Analysis.
Wu TH; Tsai YT; Chen KY; Yap WK; Luan CW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674837
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9,839 patients.
Lu X; Guo W; Xu W; Zhang X; Shi Z; Zheng L; Zhao W
Cancer Manag Res; 2019; 11():229-249. PubMed ID: 30636896
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of the modified Glasgow prognostic score in biliary tract cancer patients: a systematic review and meta-analysis.
Zhou Y; Liu Z; Cheng Y; Li J; Fu W
J Gastrointest Surg; 2024 Apr; 28(4):559-565. PubMed ID: 38583910
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
Kishi T; Matsuo Y; Ueki N; Iizuka Y; Nakamura A; Sakanaka K; Mizowaki T; Hiraoka M
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):619-26. PubMed ID: 26068494
[TBL] [Abstract][Full Text] [Related]
25. Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study.
Chen Z; Nonaka H; Onishi H; Nakatani E; Sato Y; Funayama S; Watanabe H; Komiyama T; Kuriyama K; Marino K; Aoki S; Araya M; Tominaga L; Saito R; Maehata Y; Oguri M; Saito M
J Radiat Res; 2021 May; 62(3):457-464. PubMed ID: 33866376
[TBL] [Abstract][Full Text] [Related]
26. Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta-analysis.
Luan CW; Kuo LT; Wang YT; Liao CT; Kang CJ; Lee YC; Chen KY; Lai CH; Tsai YH; Huang EI; Tsai MS; Hsu CM; Chang GH; Tsai YT
Head Neck; 2023 Jul; 45(7):1856-1867. PubMed ID: 37161915
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
Leung EY; Scott HR; McMillan DC
J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
[TBL] [Abstract][Full Text] [Related]
28. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients.
Zhao QT; Yuan Z; Zhang H; Zhang XP; Wang HE; Wang ZK; Duan GC
Int J Cancer; 2016 Jul; 139(1):164-70. PubMed ID: 26915723
[TBL] [Abstract][Full Text] [Related]
29. Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis.
Hu X; Wang Y; Yang WX; Dou WC; Shao YX; Li X
Cancer Manag Res; 2019; 11():6163-6173. PubMed ID: 31308752
[TBL] [Abstract][Full Text] [Related]
30. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer.
Osugi J; Muto S; Matsumura Y; Higuchi M; Suzuki H; Gotoh M
J Cancer Res Ther; 2016; 12(2):945-51. PubMed ID: 27461679
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Lung Cancer: A Systematic Review and Meta-Analysis.
Jin J; Yang L; Liu D; Li WM
Technol Cancer Res Treat; 2021; 20():1533033820983085. PubMed ID: 33576324
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
[TBL] [Abstract][Full Text] [Related]
35. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M
Gynecol Oncol; 2018 Jan; 148(1):36-41. PubMed ID: 29107348
[TBL] [Abstract][Full Text] [Related]
36. The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer.
Hanai N; Sawabe M; Kimura T; Suzuki H; Ozawa T; Hirakawa H; Fukuda Y; Hasegawa Y
Oncotarget; 2018 Dec; 9(97):37008-37016. PubMed ID: 30651931
[TBL] [Abstract][Full Text] [Related]
37. Glasgow prognostic score is a better predictor of the long-term survival in patients with gastric cancer, compared to the modified Glasgow prognostic score or high-sensitivity modified Glasgow prognostic score.
Hirahara N; Matsubara T; Kaji S; Kawabata Y; Hyakudomi R; Yamamoto T; Uchida Y; Ishitobi K; Takai K; Tajima Y
Oncotarget; 2020 Nov; 11(45):4169-4177. PubMed ID: 33227100
[TBL] [Abstract][Full Text] [Related]
38. Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care.
Pantano Nde P; Paiva BS; Hui D; Paiva CE
J Pain Symptom Manage; 2016 Feb; 51(2):270-7. PubMed ID: 26598040
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory markers for predicting overall survival in gastric cancer patients: A systematic review and meta-analysis.
Kim MR; Kim AS; Choi HI; Jung JH; Park JY; Ko HJ
PLoS One; 2020; 15(7):e0236445. PubMed ID: 32716955
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Significance of the Metabolic Marker Hexokinase-2 in Various Solid Tumors: A Meta-Analysis.
Liu Y; Wu K; Shi L; Xiang F; Tao K; Wang G
PLoS One; 2016; 11(11):e0166230. PubMed ID: 27824926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
